Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005254 | 1.00 | HTR1A (0.52) | HTR1ASLC6A4ALDH1A1HTTHRH3 | |
| SCHEMBL17278115 | 0.82 | SLC7A5 (0.61) | HTR1ASLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL9501079 | 0.82 | SLC6A4 (0.61) | HTR1ASLC6A4HRH3SLC6A9 | |
| SCHEMBL6004073 | 0.81 | SLC6A4 (0.61) | SLC6A4HTTHRH3SLC6A2SLC6A3 | |
| SCHEMBL8202643 | 0.81 | SLC6A4 (0.61) | SLC6A4HTTHRH3SLC6A2SLC6A3 | |
| SCHEMBL6007100 | 0.79 | SLC6A4 (0.51) | SLC6A4ALDH1A1HRH3SLC6A9SLC6A2 | |
| SCHEMBL6004079 | 0.79 | SLC6A4 (0.51) | SLC6A4ALDH1A1HRH3SLC6A9SLC6A2 | |
| SCHEMBL6006329 | 0.79 | SLC6A4 (0.51) | SLC6A4ALDH1A1HRH3SLC6A9SLC6A2 | |
| SCHEMBL5661362 | 0.79 | SLC6A4 (0.54) | SLC6A4HTTHRH3SLC6A2SLC6A3 | |
| SCHEMBL6006120 | 0.79 | SLC6A4 (0.54) | SLC6A4HTTHRH3SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| CN-1327383-A | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALERICS NEUROSCIENCE CO (US) | 2001-12-19 | — | — | CN | disclosed |
| EP-1014966-A4 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | NPS PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
| EP-1014966-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Allelix Neuroscience Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1997045115-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | TROPHIX PHARMACEUTICALS, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | HTR1A 145/4885SLC6A4 9/4885ALDH1A1 806/4885 |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC6A1, SLC18A2, SLC6A11 | HTR1A 43/4885SLC6A4 14/4885ALDH1A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.